Skeletal Survey X-Ray

PROCEDURE3 trials

Sponsors

University of Washington, Mayo Clinic, National Cancer Institute (NCI)

Conditions

Multiple MyelomaPlasma Cell MyelomaRecurrent Multiple MyelomaRecurrent Plasma Cell MyelomaRefractory Multiple MyelomaRefractory Plasma Cell Myeloma

Phase 1

Belantamab Mafodotin, Lenalidomide, and Daratumumab for the Treatment of Relapsed, Refractory, or Previously Untreated Multiple Myeloma

TerminatedNCT04892264

Mayo ClinicPlasma Cell Myeloma, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma

Start: 2021-06-03End: 2024-03-18Updated: 2025-05-18

Phase 2

Isatuximab, Carfilzomib, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma

Active, not recruitingNCT04883242

University of WashingtonRecurrent Multiple Myeloma, Refractory Multiple Myeloma

Start: 2021-07-29End: 2031-12-31Updated: 2026-09-16

Iberdomide Versus Observation Off Therapy After Idecabtagene Vicleucel CAR-T for Multiple Myeloma

SuspendedNCT06179888

National Cancer Institute (NCI)Multiple Myeloma

Start: 2024-08-27End: 2027-10-31Target: 84Updated: 2026-09-09

Related Papers

Trial in progress: CAR-T (idecabtagene vicleucel) in advanced myeloma plus iberdomide or usual monitoring (The Alliance A062102 CADMIUM Study)

Blood2025-11-03